
POLICY DETERMINATION



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

***Current Policy Effective Date: 08/21/2023**
(See policy history boxes for previous effective dates)

Title: 90678 Respiratory syncytial virus vaccine (RSVpreF)

Brief Description of Service:

Respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. People infected with RSV are usually contagious for 3 to 8 days. However, some infants, and people with weakened immune systems, can continue to spread the virus even after they stop showing symptoms, for as long as 4 weeks.¹

There is no specific treatment for RSV infection, though researchers are working to develop vaccines and antivirals (medicines that fight viruses). Steps to relieve symptoms include managing fever, pain and prevention of dehydration. In severe cases the individual may need to be hospitalized.

Abrysvo is an FDA-approved vaccine indicated for the prevention of lower respiratory tract disease caused by RSV in people 60 years of age and older and pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age. The FDA approved Abrysvo on August 21, 2023.

Recommendation:

The RSVpreF vaccine (Abrysvo) is established. The U.S. Food and Drug Administration (FDA) has approved this vaccine in the adult population and it is currently recommended by the Advisory Committee on Immunization Practices for adults.

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

90678

Other codes (investigational, not medically necessary, etc.):

N/A

References:

1. Centers for Disease Control and Prevention. Respiratory syncytial virus infection (2022). <https://cdc.gov/rsv/clinical/index.html>. Accessed September 2023.
2. Walsh EE, Falsey AR, Scott DA, et al. A randomized phase 1 and 2 study of a respiratory syncytial virus perfusion F vaccine. J Infect Dis. Apr 2022;225(8): 1357-1366.
3. Centers for Disease Control and Prevention. ACIP recommended child, adolescent and adult immunization schedule, United States, 2022-2023. <https://www.ced.gov/vaccines/schedules>. Accessed September 2023.

Joint Blue Cross/BCN Medical Policy History

| Policy Effective Date | Blue Cross Signature Date | BCN Signature Date | Comments |
|-----------------------|---------------------------|--------------------|---|
| 10/18/22 | 10/18/22 | | Joint policy established |
| 8/21/23 | 10/17/23 | | RSV vaccine now FDA approved and ACIP recommended. Status change from E/I to established. Policy retired. |

Next Review Date:
review

This is an established policy and no longer subject to periodic